A light at the end of the dark tunnel of depression? Doctors commonly prescribe antidepressants to treat patients suffering ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Cybin Inc. CYBN has launched its Phase 3 pivotal program called PARADIGM, which is aimed at testing the efficacy of its lead ...

Seasonal Affective Disorder (SAD) affects millions of Americans, and cases usually start to rise in late fall or early winter ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Bright light therapy, a standard treatment for seasonal depression, may also help people who experience depression year-round ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to present promising 12-month data from its Phase 2 study of CYB003, aimed at ...

Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can ...